There has been a further step forward towards the start of clinical trials for a novel peptide therapy to limit brain damage following ischaemic stroke.
The research is led by Clinical Professor Neville Knuckey and Professor Bruno Meloni (Perron Institute Stroke Research group).
Results of a pre-clinical study show the compatibility of the ARG-007 drug when co-administered with clot dissolving agents, alteplase and tenecteplase, used for thrombolysis.
Findings of the study, published in the Journal of Thrombosis and Thrombolysis, indicate that ARG-007 does not negatively impact alteplase or tenecteplase, nor is it degraded by them.
Based on research by the Perron Institute and The University of Western Australia, the WA-based biotechnology company Argenica Therapeutics Ltd was set up to drive forward the clinical development of this neuroprotective drug to achieve approvals and commercial availability.
The neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials.
The aim is for this potential therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.